We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
69 hedge funds and large institutions have $338M invested in Crescent Biopharma in 2017 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
226% more capital invested
Capital invested by funds: $104M → $338M (+$234M)
186% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 14
60% more funds holding
Funds holding: 43 → 69 (+26)
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
0.16% more ownership
Funds ownership: 0.82% → 0.98% (+0.16%)
70% less call options, than puts
Call options by funds: $337K | Put options by funds: $1.12M
Holders
69
Holders Change
+26
Holders Change %
+60.47%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
40
Increased
15
Reduced
10
Closed
14
Calls
$337K
Puts
$1.12M
Net Calls
-$779K
Net Calls Change
-$779K
Top Buyers
| 1 |
Jennison Associates
New York
|
+$13.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.3M |
| 4 |
Millennium Management
New York
|
+$11M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.1M |
